Ciprofloxacin is a relatively new fluoroquinolone derivative which has been shown to be highly effective against both grampositive and gram-negative bacteria including Pseudomonas aeruginosa (Hackbarth et al., 1986; Neu, 1987; Campoli-Richards et al., 1988; Demoleas & Davies, 1988; Lefevre et al., 1988; Neer, 1988) . The pharmacokinetics of ciprofloxacin were originally investigated in humans (Andriole, 1993) . It has also been investigated in dogs, rats, rabbits, monkeys, calves, pigs and ponies (Siefert et al., 1986; Barriere et al., 1987 , Walker et al., 1990 Dowling et al., 1995) . The extended antimicrobial activity, lack of plasmid-mediated resistance, large volume of distribution and minimal adverse effects of ciprofloxacin are therapeutically advantageous. Because of the great physiological differences, the pharmacokinetic parameters of ciprofloxacin for mammals cannot be extrapolated to poultry. Therefore this work was designed to evaluate the pharmacokinetic pattern of ciprofloxacin after intravenous (i.v.) and oral (p.o.) administration in broiler chickens.
Twelve healthy Hubbard broiler chickens (1.2±1.5 kg body wt) were used. They were housed in cages, fed on a balanced ration free from therapeutic agents and water was available ad libitum.
Ciprofloxacin hydrochloride (VAPCO, Amman, Jordan) was administered as a bolus into the wing vein at a single dose of 5 mg/kg body wt into six chickens. The remaining six chickens were given ciprofloxacin orally via a stomach tube in the same dose after a fasting period of 18 h. Blood samples were withdrawn at 5, 10, 15, 30 min and 1, 2, 4, 6, 8, and 24 h after drug administration. Blood samples (1 mL) were collected in heparinized tubes from the contralateral wing vein through a fine plastic intravenous catheter. Plasma was separated by cold centrifuge at 3000 g for 5 min, stored at 7208C and assayed for ciprofloxacin within 3 days of sample collection. Plasma ciprofloxacin concentrations were determined using the agar well diffusion assay as described by Bennet et al., (1966) , using Escherichia coli (ATCC 25922) as test organism (Dowling et al., 1995) . Standard concentrations were prepared using ciprofloxacin of known purity (Sigma Chemical Co., St. Louis, MO, USA). Ciprofloxacin was initially diluted in phosphate buffer (7M, pH 7.2) and known amounts were added to normal pooled plasma collected from non-treated chickens. The mean diameter of zones of bacterial inhibition in three sets was measured (mm) and the standard curve was established by linear regression. The mean correlation coefficient (r 2 ) of the standard curve was 0.998. The lower limit of sensitivity of the ciprofloxacin assay was 0.015 mg/mL.
A computerized curve stripping software program based on statistical moment theory (Yamaoka et al., 1978) was used for data analysis for each bird. The initial estimates of the modeldependent pharmacokinetic parameters (A, a, B and b) were obtained as described by Baggot (1977) and Gibaldi and Perrier (1982) . These parameters were used to calculate the actual rate constants k 12 , k 21 and k el ), the half-lives of distribution and elimination (t 1/2a , t 1/2b ), steady-state volume of distribution (V dss ), volume of distribution by the area method (V darea ) and the total body clearance (Cl B ). The area under the curve (AUC) and the area under the first moment curve (AUMC) were calculated from zero time to the last data point by the trapezoid rule.
The rate of absorption after oral administration (k a ) was calculated from the slope of the percentage of ciprofloxacin remaining to be absorbed. The mean residence time was calculated as follows: MRT=AUMC/AUC. The mean absorption time was calculated from the equation:
The oral bioavailability for each bird was calculated by comparing area under the curve after oral administration of ciprofloxacin in each bird to the mean area under the curve obtained after intravenous administration of ciprofloxacin to six birds.
The bioassay technique used for determination of ciprofloxacin in plasma of chickens gave satisfactory limits of sensitivity characteristic of this group of antibiotics. The lower limit of sensitivity of ciprofloxacin in this study (0.015 mg/mL) was similar to the previously recorded limits in plasma of other animal species (Barriere et al., 1987; Dowling et al., 1995) . This finding confirms the previous suggestion that the microbiological and high-performance liquid chromatography (HPLC) assays of ciprofloxacin are of generally similar sensitivity and in good agreement (Campoli-Richards et al., 1988) . In this study the reported ciprofloxacin concentration in plasma of chickens, 24 h after i.v. or p.o. routes (Fig. 1) Table 1 . Pharmacokinetic parameters that describe the disposition of ciprofloxacin (5 mg/ kg body wt) after intravenous and oral administration in six chickens chickens vs. time data were best described by a 2-compartment open model. This result is in agreement with those previously reported in humans (Wise et al., 1984; Dudley et al., 1987) , and animal species such as pigs and calves (Nouws et al., 1988a) , dogs (Abadia et al., 1994) , ponies (Dowling et al., 1995) , fish (Nouws et al., 1988b) and for other fluoroquinolones in broiler chickens (Anadon et al., 1995) . Following i.v. administration, the distribution half-life (t 1/2a ) of ciprofloxacin in chickens was nearly similar to that reported in pigs (Nouws et al., 1988a) . The V dss (1.132 L/kg) and V darea (2.02 L/kg) were less than those reported in mammals (Siefert et al., 1986; Barriere et al., 1987; Campoli-Richards et al., 1988; Nouws et al., 1988a; Dowling et al., 1995) . However their value was more than 1 L/kg suggesting extensive penetration of ciprofloxacin into tissue. This could be attributed to high lipid solubility and low plasma protein binding. The high k 21 /k 12 (2.8) ratio indicates that the drug moves freely between the body compartments. A similar conclusion was reached for enrofloxacin in rabbits (Broome et al., 1991) . Ciprofloxacin is slowly eliminated from chickens. The t 1/ 2b (540.63 min) was nearly similar to that reported in trout (672 min, Nouws et al., 1988b) but it was longer than that reported in humans (Bergan et al., 1986) , other mammalian species (Barriere et al., 1987; Nouws et al., 1988a; Abadia et al., 1994; Dowling et al., 1995) and fish (Nouws et al., 1988b) . Qualitative and quantitative differences in drug metabolism and excretion between mammals and birds may have contributed to these results. It is worth noting that the elimination half-life of ciprofloxacin in chickens is comparable to that of enrofloxacin in the same species which was 10.29 + 0.45 h (Anadon et al., 1995) . The Cl B value (1.54 mL/min . kg) was much lower than that reported in ponies (18.12 mL/min . kg, Dowling et al., 1995) but it was nearly similar to that of enrofloxacin in chickens (2.23 mL/ min . kg, Conzelman et al., 1987) . This low Cl B value also confirms the suggestion that fluoroquinolones are slowly eliminated from chickens.
Following oral administration, the absorption half-life (t 1/2a ; 0.21 h) and the time to maximum concentration (t max ; 42.5 min) indicate that ciprofloxacin is rapidly absorbed in chickens, but the absorption extends over a long period (MAT, 6.98 h). However the t 1/2a was much longer than that reported in dogs (Abadia et al., 1994) , ponies (Dowling et al., 1995) and calves (Nouws et al., 1988a) and it was much shorter than that reported in fish (Nouws et al., 1988b) . The observed t max in chickens was within the range reported in humans (0.5±2 h). The oral bioavailability (F) of ciprofloxacin indicates incomplete absorption from chicken gut. The F% (70.09%) was nearly similar to that reported for humans (Campoli-Richards et al., 1988) and comparable to that of enrofloxacin in chickens (Conzelman et al., 1987) . However the oral bioavailability was much higher than that reported in ponies (6.8%; Dowling et al., 1995) . It is suggested, on the basis of plasma ciprofloxacin concenrations and the reported minimum inhibitory concentrations for avian pathogenic microorganisms, that administration of 5 mg/kg, given orally at 24 h intervals, should be adequate for control of avian bacterial diseases.
